Additionally, EphA2 upregulation has been observed in liver, prostate cancer, glioblastoma, esophageal squamous cell carcinoma, ovarian cancer, and melanoma, with the highest levels detected in the most invasive tumor cells [17]. Here, EPHA2 is linked to neoplasm.